Beruflich Dokumente
Kultur Dokumente
Caso clnico 2
Exploracin fsica
Peso: 86 kg
2
IMC: 32 kg/m
Presin: 135/82 mmHg
Pie: Monofilamento 8/8. Pulsos pedios presentes.
Fondo de ojo (hace un ao): normal
HbA1c 8,9 %
Glucemia basal 230 mg/dl
Colesterol total 210 mg/dl
Colesterol HDL 47 mg/dl
MDRD 65 mg/dl
Cociente 35 mg/g
albmina/creatinina
ECG: RS sin
alteraciones
Otros datos:
Antecedentes familiares:
Madre diabtica.
Antecedentes personales:
Estilos de vida
Ferroviario jubilado.
Tiene buen soporte familiar.
habiendo dejado de fumar, las cifras de glucemia capilar en el autoanlisis son muy altas (200-250 mg/dl).
Siempre ha escuchado de profesionales sanitarios que si no se cumple con el tratamiento prescrito (modificacin
de estilos de vida y toma de frmacos) habra que ponerle insulina.
Bibliografa relacionada
1. Grupo de trabajo de la Gua de Prctica Clnica sobre Diabetes tipo 2. Gua de Prctica Clnica sobre Diabetes tipo 2.
Madrid: Plan Nacional para el SNS del MSC. Agencia de Evaluacin de Tecnologas Sanitarias del Pas Vasco; 2008.
Guas de Prctica Clnica en el SNS: OSTEBA N 2006/08
2. NICE (National Institute for Health and Clinical Excellence). Type 2 diabetes: the management of type 2 diabetes (update)
Clinical guideline. Disponible en: http://www.nice.org.uk/Guidance/CG66/Guidance/pdf/English
3. Dailey GE, III, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination
with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116(4):223-9.
4. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus
inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-
controlled, parallel-group study. Clin Ther. 2005; 27(10):1535-47.
5. Ko GT, Tsang PC, Wai HP, Kan EC, Chan HC. Rosiglitazone versus bedtime insulin in the treatment of patients with
conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. Adv Ther. 2006; 23(5):799-808.
6. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in
the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care. 2003;
26(8):2238-43.
7. Rosenstock J, Sugimoto D, Strange P,Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine
or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care.
2006; 29(3):554-9.
8. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral
hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004; (4):CD003418.
9. Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral
hypoglycemic agents? A randomized trial in primary care. J Fam Pract. 2004;53(5):393-9.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of
hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus
statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care
2009; 32:193203
11. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. Continuing metformin when starting insulin in patients with Type 2
diabetes: a double-blind randomized placebo-controlled trial. Diabet Med. 2005; 22(5):634-40.
12. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin
(human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007; (2):CD005613.
13. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine:
a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28(4):950-5.
14. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin
analogue, insulin glargine. Health TechnolAssess. 2004; 8(45):iii, 1-iii,57.
15. [DRAFT] Long-acting insulin analogues for the treatment of diabetes mellitus:meta-analyses of clinical outcomes. Update
of CADTH Technology Report No. 92. Ottawa: Canadian Agency for Drugs and Technologies in Heath; 2007
16. Pinelli NR, Cha R, Brown MB, Jaber LA. Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A
Meta-Analysis. Ann Pharmacother 2008; 42:1541-51.
17. Hermansen K,. Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,
sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and
metformin . Diabetes Obes Metab. 2007; 9:733-745
18. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2
diabetes : a randomized trial. Ann Intern Med 2005; 143:559-569.